A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Trial Profile

A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs ABBV 221 (Primary)
  • Indications Breast cancer; Colon cancer; Colorectal cancer; Glioblastoma; Head and neck cancer; Male breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Jun 2017 Preliminary results (Data cut off 11 January 2017, n=42) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 27 Jan 2017 Planned number of patients changed from 80 to 90.
    • 27 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top